Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy

Bibliographic Details
Main Authors:	Soh Mee Park, Yu Jung Kim, Ju‐Yeun Lee
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Cancer Medicine
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor
by: Guiming Deng, et al.
Published: (2024)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
by: Yuan Meng, et al.
Published: (2024)

Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
by: Shuling Shi, et al.
Published: (2024)

Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma
by: Angela E. Alnemri, et al.
Published: (2024)

Early identification of severe immune checkpoint inhibitor associated myocarditis: From an electrocardiographic perspective
by: Yongyin Gao, et al.
Published: (2024)

Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
by: Yi Zheng, et al.
Published: (2024)

Lymphocyte activation markers predict the therapeutic response to immune checkpoint inhibitors: A case–control study
by: Takuya Iwamoto, et al.
Published: (2024)

Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real‐world analysis
by: Toru Kadono, et al.
Published: (2024)

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
by: Tadashi Nishimura, et al.
Published: (2024)

Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer
by: Yiran Rong, et al.
Published: (2024)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024)

Effect of body mass index and cholesterol‐rich apolipoprotein‐B‐containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors‐based therapy: A retrospective analysis
by: Zixin Hu, et al.
Published: (2024)

Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis
by: Shoutao Dang, et al.
Published: (2024)

Notch signaling genes and CD8+ T‐cell dynamics: Their contribution to immune‐checkpoint inhibitor therapy in oral squamous cell carcinoma: A retrospective study
by: Kazuhiro Ogi, et al.
Published: (2024)

Sex‐based immune microenvironmental feature heterogeneity in response to PD ‐1 blockade in combination with chemotherapy for patients with untreated advanced non‐small‐cell lung cancer
by: Xiaofeng Yu, et al.
Published: (2024)

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma
by: Cecilia Monge, et al.
Published: (2024)

Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial
by: Ruizhen Li, et al.
Published: (2024)

The augmentation of cytotoxic immune cell functionality through physical exertion bolsters the potency of chemotherapy in models of mammary carcinoma
by: Bingqing Qin, et al.
Published: (2024)

Role of immune checkpoint inhibitors combined with chemotherapy in recurrent drug‐resistant gestational trophoblastic neoplasia: Four case reports and literature review
by: Weiqing Liu, et al.
Published: (2024)

Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin‐based chemotherapy using short hydration: A randomized phase II trial
by: Eriko Murakami, et al.
Published: (2024)

Strategies for increasing accrual in cancer clinical trials: What is the evidence?
by: Margo Michaels, et al.
Published: (2024)

Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
by: Xuemei Zhang, et al.
Published: (2024)

Impact of intra‐tumoral immunity on predicting response and survival after neoadjuvant cisplatin‐based chemotherapy in patients with muscle invasive bladder cancer
by: Alberto Mendoza‐Valderrey, et al.
Published: (2024)

The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre‐clinical study
by: Kaan Low, et al.
Published: (2024)

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial
by: Ken Kato, et al.
Published: (2024)

Recurrence‐free survival dynamics following adjuvant chemotherapy for resected colorectal cancer: A systematic review of randomized controlled trials
by: Emma Vail, et al.
Published: (2024)

Understanding the financial cost of cancer clinical trial participation
by: Courtney P. Williams, et al.
Published: (2024)

Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein‐1 inhibitors: A promising treatment approach for high‐burden hepatocellular carcinoma
by: Shumin Fu, et al.
Published: (2024)

Mass Spectrometry‐Driven Proteomic Biomarkers for Serum‐Based Detection of Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm‐Associated Invasive Carcinoma
by: HyunGyo Jung, et al.
Published: (2026)

Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
by: Jiyun Lee, et al.
Published: (2024)

Enhanced CTLA‐4 blockade anti‐tumor immunity with APG‐157 combination in a murine head and neck cancer
by: Daniel Sanghoon Shin, et al.
Published: (2024)

A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
by: Tao Li, et al.
Published: (2024)

Identification and Validation of Serum Biomarkers to Improve Colorectal Cancer Diagnosis
by: Minha Lea Yoon, et al.
Published: (2024)

Correction to “Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events”
Published: (2024)

TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic
by: Karen Lisa Smith, et al.
Published: (2024)

PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence
by: Litang Huang, et al.
Published: (2024)

Prognostic impact of bridge or neoadjuvant induction chemotherapy in patients with resected oral cavity cancer: A nationwide cohort study
by: Cheng‐Lung Hsu, et al.
Published: (2024)

Examining the involvement of guardians of children with acute lymphoblastic leukemia in Tanzania as public contributors to inform the design and conduct of the GuardiansCan project: A mixed‐methods study protocol
by: Faraja Chiwanga, et al.
Published: (2024)

Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials
by: Adam Khan, et al.
Published: (2024)

Targeted agents in patients with progressive glioblastoma—A systematic meta‐analysis of randomized clinical trials
by: Franziska Maria Ippen, et al.
Published: (2024)

Similar Items

Similar Items